April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Structural changes of choroidal neovascularization in indocyanine green angiography after intravitreal ranibizumab injection
Author Affiliations & Notes
  • Hyun Woong Kim
    Ophthalmology, Inje University, Busan, Republic of Korea
    Ophthalmology, Busan Paik Hospital, Busan, Republic of Korea
  • Ji Eun E Lee
    Ophthalmology, Pusan National University, Yangsan, Republic of Korea
    Medical Institute, Pusan National University Hospital, Busan, Republic of Korea
  • Sang Joon Lee
    Ophthalmology, Gospel hospital, College of medicine, Kosin university, Busan, Republic of Korea
  • Joo Eun Lee
    Ophthalmology, Inje University, Busan, Republic of Korea
    Ophthalmology, Haeundae Paik Hospital, Busan, Republic of Korea
  • Il Han Yun
    Ophthalmology, Inje University, Busan, Republic of Korea
    Ophthalmology, Busan Paik Hospital, Busan, Republic of Korea
  • Footnotes
    Commercial Relationships Hyun Woong Kim, None; Ji Eun Lee, Novartis (F); Sang Joon Lee, None; Joo Eun Lee, None; Il Han Yun, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3403. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hyun Woong Kim, Ji Eun E Lee, Sang Joon Lee, Joo Eun Lee, Il Han Yun; Structural changes of choroidal neovascularization in indocyanine green angiography after intravitreal ranibizumab injection. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3403.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the mechanism of choroidal neovascularization (CNV) recurrence followed by intravitreal ranibizumab injections based on vascular structural changes of choroidal neovascularization (CNV) using indocyanine green angiography (ICGA)

Methods: A total of 31 patients with exudative age-related macular degeneration and CNV whose structures were identifiable in ICGA. Patients with either polypoidal choroidal vasculopathy or retinal angiomatous proliferation were excluded. Ranibizumab was injected into the vitreous cavity once a month for 3 months, and then as needed for the following 3 months. Fluorescein angiography (FA) and ICGA were performed at baseline, 3 and 6 months. Vascular structures of CNV were described as arterio-venular (A-Vular) and capillary components, and structural changes were assessed in ICGA.

Results: Arteriolar components were observed in 29 eyes (94%). Regression of the capillary components was observed in most cases. Two eyes, having purely capillary, components showed complete regression of CNV leaving non-fibrotic scar at 3 months. Although regression of A-Vular component was noted in 14 eyes (48%), complete resolution was not observed. The eyes were categorized into 3 groups according to CNV structural changes- the regressed (group R, 10 eyes, 31%), the matured (group M, 7 eyes, 23%) and the growing (group G, 14 eyes, 45%). In group R, there was no regrowth of CNV found at 6 months. In group M, distinct vascular structures were observed at 3 months and persisted without apparent changes at 6 months. In group G, growth or reperfusion of capillary components from the persisting A-Vular components was noted at 6 months. The BCVA of group G was significantly worse at baseline, 3 and 6 months.

Conclusions: Capillary components were regressed as well as matured during anti-VEGF treatment. Loading monthly ranibizumab injections for 3 months showed limited efficacy in regressing A-Vular components entirely, which was the underlying reason in CNV recurrence

Keywords: 412 age-related macular degeneration • 748 vascular endothelial growth factor  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×